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Abstract
Background: Extracellular vesicles (EVs) act as key mediators of intercellular communication and are secreted and
taken up by all cell types in the central nervous system (CNS). While detailed study of EV-based signaling is likely to
significantly advance our understanding of human neurobiology, the technical challenges of isolating EVs from CNS
tissues have limited their characterization using ‘omics’ technologies. We therefore developed a new Protein Organic
Solvent Precipitation (PROSPR) method that can efficiently isolate the EV repertoire from human biological samples.
Results: In the current report, we present a novel experimental workflow that outlines the process of sample
extraction and enrichment of CNS-derived EVs using PROSPR. Subsequent LC-MS/MS-based proteomic profiling of EVs
enriched from brain homogenates successfully identified 86 of the top 100 exosomal markers. Proteomic profiling of
PROSPR-enriched CNS EVs indicated that > 75 % of the proteins identified matched previously reported exosomal and
microvesicle cargoes, while also expanded the known human EV-associated proteome with 685 novel identifications.
Similarly, lipidomic characterization of enriched CNS vesicles not only identified previously reported EV-specific lipid
families (PS, SM, lysoPC, lysoPE) but also uncovered novel lipid isoforms not previously detected in human EVs. Finally,
dedicated flow cytometry of PROSPR-CNS-EVs revealed that ~80 % of total microparticles observed were exosomes
ranging in diameter from ≤100 nm to 300 nm.
Conclusions: These data demonstrate that the optimized use of PROSPR represents an easy-to-perform and
inexpensive method of enriching EVs from human CNS tissues for detailed characterization by ‘omics’ technologies. We
predict that widespread use of the methodology described herein will greatly accelerate the study of EVs biology in
neuroscience.
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Background
The emerging roles played by extracellular vesicles (EVs)
in cognition, neuropathology and neurotherapeutics have
rendered the characterization of these structures from
central nervous system (CNS) tissues as a key challenge of
current neuroscience [1]. It has been proposed that EVs
might mediate the advance of neurodegeneration in amyo-
trophic lateral sclerosis (ALS) [2], Parkinson’s disease
(PD) and Alzheimer’s disease (AD) (see Budnik et al. [3]
for detailed review). By contrast, recent reports suggest
that EVs may reduce chronic neuroinflammation and may
help oligodendrocytes to tolerate oxidative stress insults
during neurodegeneration [4–6].
All families of cells in the CNS can release a diverse
repertoire of EVs ranging in diameter from 30–1500 nm
[7]. These vesicles are released from multivesicular bod-
ies within neurons and glial cells and express hallmark
EV proteins including major histocompatibility complex
(MHC), endosomal sorting complexes required for trans-
port (ESCRT) and tetraspanins, which have previously
been identified as common markers of EVs derived from
other tissues [8, 9]. Microvesicles are larger and more het-
erogeneous than exosomes, and are typically shed from
the plasma membrane by randomized blebbing [10].
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Due to their increased size, microvesicles may contain
fragments of nuclear material or even intact organelles
that can be then conveyed to remote sites via the circula-
tion [10]. Although distinctive features based on the diam-
eter range of EVs have been encountered, it is known that
exosomes and microvesicles express common markers
and share common molecular cargoes what makes im-
perative their analysis at a global scale [3, 11].
Only trace levels of EVs are present in CNS tissues,
hence direct analysis of these bodies and their cargoes
by ‘omics’ technologies depends on enrichment strat-
egies that can reduce the background soluble proteins,
proteinaceous aggregates, and proteolytic contaminants
[12, 13]. While ultracentrifugation is considered the current
‘gold-standard’ method to enrich a wide and untargeted
population of EVs from biological samples, this approach is
not only time-consuming but also unstandardized and re-
quires large sample volumes [14, 15]. It is in-part due to
these technical constraints that, to our knowledge, the
CNS-derived EVs repertoire has not yet been characterized
in detail, and the potential benefits of exploiting human
EVs biology in clinical settings have yet to be determined.
We recently developed a novel method termed PRotein
Organic Solvent PRecipitation (PROSPR) that can enrich a
diverse repertoire of EVs from human blood plasma, and
provides several major advantages over classical ultracen-
trifugation methods [16]. PROSPR represents a simple,
standardized, three-step procedure that pellets soluble
proteins and other contaminants during a brief centrifuga-
tion cycle while leaving the enriched EVs behind in the or-
ganic solvent fraction. In contrast to ultracentrifugation,
this quick method is extremely simple to use, enables
high-efficient enrichment of EVs from only small amounts
of initial sample and additionally the precipitated proteins
from hydrophilic tissue can be easily used in further exper-
iments. In the current study, we used an optimized
PROSPR protocol to enrich EVs from human and mouse
CNS tissues (PROSPR-CNS-EVs), thereby obtaining a di-
verse arrays of CNS-derived EVs suitable for detailed
characterization using ‘omics’ technologies. This new
method will significantly aid future studies in the emerging
neuroscientific field of EVs biology by simplifying the en-
richment of these structures from CNS tissues. Prelimin-
ary results were presented in abstract form [17].
Results
Lipidomic profile of human PROSPR-CNS- EVs
Lipidomic profiling of CNS-derived EVs is critical to
understand the emerging roles played by these structures
in key neurological processes. In the current study, we ana-
lyzed the lipidome of PROSPR-CNS-EVs enriched from
~150 mg of human brain using direct infusion electrospray
ionization tandem mass spectrometry (ESI-MS/MS) in
positive and negative modes (whole list of identifications
can be found in Additional file 1: Dataset 1). As shown in
Fig. 1a, this approach enabled us to detect 10 different lipid
classes, including several hallmark components of human
EVs; phosphatidylserines (PS), sphingomyelins (SM), lyso-
phosphatidylcholines (lysoPC), phosphatidylglycerol (PG)
and lysophosphatidylethanolamine (lysoPE) [18]. The dis-
tribution profile of lipid classes obtained from PROSPR-
CNS-EVs was comparable to that obtained from cancer
enriched EVs [18].
Fig. 1 Lipidomics characterization of PROSPR-CNS-EVs. a Profile of
lipid classes identified in EVs lipidome including percentage of
identification of EV-characteristic lipids* [18]. b Characterized lipid
isoforms were compared with whole brain lipidome (+ identifies those
lipids found in whole brain lipidome) and matched to records in the
EV databases Exocarta [18], Vesiclepedia [19] and EVpedia [21]. Matched
lipid isoforms are shown in colors according to their EVs databases
match whereas non-matched isoforms are shown in black
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Further lipidomic characterization of PROSPR-CNS-
EVs allowed identification of 43 different isoforms that
were searched in the EV databases Exocarta [19, 20],
Vesiclepedia [21] and EVpedia [22] (Fig. 1b). This ana-
lysis revealed that the majority of lipid isoforms identi-
fied in PROSPR-CNS-EVs were novel species that did
not match existing EV lipid records (only 37.5 % were
registered in Vesiclepedia, 37.5 % in EVpedia and 25.6 %
in Exocarta). From these novel EV-associated lipids we
highlight the identification of the following isoforms
belonging to the EV-characteristic class of lipids PS:
PS36:2, PS40:4 and PS40:6. The lipidomic profile of
whole brain tissue was also characterized in our study
(Additional file 2: Dataset 2). Following this analysis only
16 of the previous 43 lipid isoforms identified in PROSPR
fractions were identified in whole brain fractions (Fig. 1b).
These results suggested that EVs derived from CNS tissues
display characteristic lipid profiles that can be successfully
enriched by PROSPR and characterized by lipidomics.
Proteomic profile of human PROSPR-CNS-EVs
A total 2901 proteins were identified in PROSPR-CNS-
EVs (Additional file 3: Dataset 3). Comparison of these
proteins against records in Vesiclepedia and EVpedia
[21, 22] revealed that 76.1 % of the total PROSPR-
CNS-EV proteome was previously identified in enriched
microvesicle fractions (Fig. 2a). Similarly, 33.2 % of the
total PROSPR-CNS-EV proteins were identified in
enriched exosomal fractions (Fig. 2a), including 86 pro-
teins that matched the top 100 most common exosomal
markers listed in Exocarta [19] (Fig. 2b). We achieved
high-confidence identification of multiple essential EV
markers including Alix, ESCRT proteins, tetraspanins
(CD9, CD81 and CD82), and 15 different members of the
vacuolar protein sorting family, as well as MHC-I, MHC-
II, and the ERM family proteins ezrin, radixin, moesin,
flotillin-1 and flotillin-2 (Additional file 3: Dataset 3). We
then analyzed the proteome from whole brain considered
as the CNS starting material prior to enrichment of EVs
(Additional file 4: Dataset 4). We found that only 1228
proteins from whole brain proteome matched previous re-
cords in EV-specific databases (Additional file 5: Figure
S1a) in front of 2216 proteins that matched same records
from PROSPR-CNS-EV fractions (Fig. 2a). Additionally,
we quantified by LC-MS/MS label-free quantitation [23]
the most abundant proteins in whole brain proteome
(HBB, HBA2, HBA1, VIM and HBD). We found that
PROSPR fractions contained on average less than three
percent of the whole brain amount for these top five high
abundant proteins (Fig. 2c). Finally, we analyzed the
percentage of membrane proteins in PROSPR-CNS-
EVs using FunRich [24], an open software that uses
customized pearl scripts to analyze functional and clinical
data of proteins compiled in several databases (detailed
information of Funrich software can be found in http://
funrich.org/faq). Membrane proteins commonly represent
≥ 30 % of the total proteins in EVs-enriched fractions
[22, 25, 26] and we found that these proteins represent
the 42.43 % of total identified proteins in PROSPR-CNS-
EVs. These data further confirmed that PROSPR enables
rapid, high-efficient enrichment of EVs from human CNS
tissues.
Comparison of PROSPR and ultracentrifugation
techniques for enrichment of CNS-EVs
Data obtained from PROSPR-CNS-EVs was compared to
data obtained from sucrose-cushion ultracentrifugation
(Ultra-CNS-EVs) as shown in Fig. 2d. In both method-
ologies EVs were enriched from ~150 mg of human
brain tissue. This analysis revealed that PROSPR was
able to enlarge the enrichment of vesicle-associated pro-
teins by 7.2-fold and of exosome-associated proteins by
6.9-fold compared to ultra-cushion (Fig. 2d). Additionally,
a total of 126 CNS proteins that were not previously iden-
tified in EV specialized databases were commonly identi-
fied in PROSPR-CNS-EVs and Ultra-CNS-EVs (Fig. 2d).
Further analysis of these EV proteins revealed that 72 pro-
teins were also identified in whole brain proteome
whereas 54 proteins were only identified in enriched EV
fractions (Fig. 2d). Detailed list of these novel CNS-EV
molecules can be found in Additional file 6: Dataset 5.
A total of 568 novel species (23.6 % of the total identi-
fied proteins) that did not match either with our identified
proteins in Ultra-CNS-EVs nor with existing record in EV
specialized databases were also identified in PROSPR-
CNS-EV fractions (Fig. 2d). These unique proteins from
PROSPR-CNS-EV fractions and the 118 unique proteins
identified from Ultra-CNS-EVs fractions were then
matched with our identified whole brain proteome to de-
termine the percentage of whole brain contamination in
enriched EVs. We found that whole brain proteins repre-
sented only the 6.9 % of these unique proteins in
PROSPR-CNS-EVs compared to the 33.9 % that repre-
sented in Ultra-CNS-EVs fractions (Additional file 5:
Figure S1b). Furthermore, these novel identified EV
molecules from PROSPR fractions included several
key brain proteins as multiple S-100 isoforms, brain
signaling mediators CAMK2A and sirtuins, neuropeptide
NPY, and a wide range of synaptic proteins as synapsins
and synaptopodins (a complete list of PROSPR-CNS-
EV unique proteins including the 126 common with
Ultra-CNS-EV fractions can be found in Additional file 7:
Dataset 6).
Functional analysis of these novel PROSPR-CNS-EV
identifications was performed in FunRich [24]. This ana-
lysis identified a large portion of these proteins as cere-
bellum and hippocampus characteristic proteins, fact
that could provide information about the sites of origin
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Fig. 2 (See legend on next page.)
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of these novel identified EV-associated molecules in the
temporal lobe (Fig. 2e). Furthermore, 15 % of the novel
proteins were associated with the cellular plasma mem-
brane, lysosome or cytoskeleton (Fig. 2f ). Intriguingly,
~50 % of these previously unknown EV-proteins were
also associated with malignant glioma (Fig. 2e), thereby
emphasizing the potential of EVs to inform researchers
about key pathological processes in the CNS.
Characterization of human PROSPR-CNS-EVs by dedicated
flow cytometry
Size distribution of EVs freshly isolated from human
brain tissue was analyzed by dedicated flow cytometry
(dFC) as previously described [27, 28]. Microparticle
gates were set after the assessment of commercial latex
beads from three standard EV sizes (100 nm, 300 nm
and 500 nm) (Fig. 3a-c). According to our measurements
the EVs stained by the phospholipid-specific dye FM 1-
43FX represented the 83.32 ± 0.65 % of the total material
in PROSPR-CNS-EV preparations (Fig. 3d). Gated ana-
lysis of stained vesicles revealed that 74.65 ± 2.68 % of
these particles were placed at the lower exosome range
(≤ 100 nm), 8.51 ± 1.11 % of these particles were gated at
the higher exosome range (300 nm), 3.49 ± 0.17 % were
placed at the lower microvesicle range (500 nm) and the
remaining 13.34 ± 1.43 % were revealed as microvesicles
displaying diamaters bigger than 500 nm (Fig. 3e). Fur-
thermore, dFC analysis confirmed the low presence of
whole organelle contamination in PROSPR-CNS-EVs
since less than 10 % of total identified microparticles
were detected at the bigger diameter range (≥ 700 nm).
Proteomic profile of PROSPR-CNS-EVs enriched from
mouse tissues
A total of 469 proteins were identified in PROSPR-CNS-
EVs enriched from ~40 mg of mouse brain tissue (Add-
itional file 8: Dataset 7). From these proteins, the 42 %
were matched with previous exosome data compiled in
Exocarta and Funrich databases, the 33 % were matched
with previous microvesicle data from Vesiclepedia and
EVpedia and the 49.5 % were considered novel identifi-
cations (Fig. 4a). We then performed functional
enrichment analysis of these novel mouse PROSPR-
CNS-EV protein identifications as shown in Fig. 4b and c.
Signal transduction and cell communication were the most
common functions of these analyzed proteins although at a
lesser proportion they were also involved on cell growth,
cellular transport and metabolism (Fig. 4b). Analysis of cel-
lular association revealed the presence of plasma mem-
brane, cytoskeletal and lysosomal proteins as previously
observed in novel EV proteins from human CNS tissues
(Fig. 4c). Globally, these results demonstrated that PROSPR
was also able to enrich EVs from mouse CNS tissues.
Discussion
Analysis of EVs released in vitro by neuron cells has sug-
gested key roles for these structures on human neuro-
biology and neuropathology, but extrapolation of these
findings to in vivo experiments has been hindered by the
lack of efficient methods for enriching EVs from CNS
tissues. Ultracentrifugation techniques are commonly
used to enrich EVs from biological samples, but this ap-
proach pellets-down a high amount of contaminating
soluble proteins and aggregates that complicate analysis
using ‘omics’ platforms [29, 30]. Indeed, while repeated
ultracentrifugation coupled with density gradient separ-
ation can enable targeted validation of specific proteins in
brain exosomes using highly sensitive biochemical tech-
niques [31], the sample volumes generated are often insuf-
ficient to permit detailed EV characterization using
common ‘omics’ approaches [32]. We therefore developed
PROSPR as an easy-to-perform and standardized method
that can efficiently enrich EVs from complex biological
fluids [16]. PROSPR uses the inexpensive and widely
available solvent acetone to precipitate out hydrophilic
species and leave intact hydrophobic EVs behind in so-
lution [16, 33]. As expected, we found that ultracentri-
fugation coupled with a sucrose cushion although it
was able to enrich EVs from CNS tissues it was pellet-
ing down ~5 times more of whole brain contaminants
than PROSPR. Similarly, due to its ability to clean EVs
fractions from hydrophilic contaminants, we found that
7.2-fold more of low abundant vesicle-associated proteins
and 6.9-fold more of low abundant exosome-associated
(See figure on previous page.)
Fig. 2 Proteomics characterization of human PROSPR-CNS-EVs. a Venn diagram of EV proteins matched to records in the EV databases Exocarta
[19], Vesiclepedia [21] and EVpedia [22]. Of the total 2901 proteins identified, 61.8 % were associated with exosome markers and cargoes, 75.4 %
were associated with microvesicle markers and cargoes and 23.6 % were novel identifications in brain EVs. b List of 86 exosomal markers matched
to top 100 exosomal markers in Exocarta. Top 10 of common exosomal markers were indicated in red. c Label-free quantitation of the top five
most abundant proteins from whole brain proteome compared to their abundance in PROSPR-CNS-EVs. PROSPR-CNS-EV fractions contained on
average less than three percent of whole brain amount of the top five highest abundant proteins. d Venn diagram of proteins identified from
Ultra-CNS-EVs matched to PROSPR-CNS-EVs and EV protein records in Vesiclepedia [21] and Exocarta [19]. Unique 126 EV proteins found in common
between Ultra-CNS-EVs and PROSPR-CNS-EVs were compared to whole brain proteome and 72 of these CNS-EV markers were also identified in whole
brain whereas 54 were only identified in EVs enriched fractions. Complete list of these proteins is reported in the Additional file 6: Dataset 5 e Funrich
[24] site of expression analysis of novel identified EV proteins from PROSPR-CNS-EVs fractions. f Funrich cellular origin categories of novel identified
proteins from PROSPR-CNS-EVs fractions
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proteins were identified in PROSPR-CNS-EVs compared
to Ultra-CNS-EVs.
Consistent with previous reports, our proteomic data in-
dicated that PROSPR-CNS-EVs displayed common EV
hallmarks and cargoes [19, 21, 22], but also incorporated
specific brain proteins not previous identified in EVs. These
novel EV components included myelin proteins, multiple
synaptic proteins, neurotransmitter receptors, and essential
brain kinases. These data were consistent with previous
reports demonstrating that EVs mediate intercellular com-
munication between glial cells and neurons [34–36]. Add-
itionally, a large proportion of the previously unknown EV
proteins were associated with plasma membrane domains,
suggesting that some of these molecules may represent
brain-specific EV markers, although further research will be
required to confirm this hypothesis. As previously reported
by Kim et al. [22], Minciacchi et al. [25], Simpson et al.
[26], membrane proteins represent ≥30 % of total proteins
identified in quality isolated EV preparations. Consistent
with this expectation, membrane proteins in PROSPR-
CNS-EVs fractions represented ~43 % of all identified pro-
teins. Furthermore, application of PROSPR to mouse CNS
tissues as depicted in methods section of this manuscript,
demonstrated that PROSPR was also able to successfully
enrich EVs from small amounts of CNS tissue enabling
characterization of CNS-EVs from in-vivo disease models.
Fig. 3 Characterization of PROSPR-CNS-EVs by dedicated flow cytometry (dFC). Microparticle gates for EV size distribution analysis were set after
the testing of commercial latex beads from three standard EV sizes. a Gate determination of 100 nm beads. b Gate determination of 300 nm
beads. c Gate determination of 500 nm beads. d dFC measurement of PE signal from phospholipid-specific stained EVs. The gate for phospholipid-
stained vesicles (R8) shows that 83.32 ± 0.65 % of the total material in PROSPR-CNS-EVs was positively stained. e Size distribution of EVs by gated
analysis of stained particles from PROSPR-CNS-EVs. Lower exosomal range (≤ 100 nm) represented 74.65 ± 2.68 % of total identified microparticles.
Higher exosomal range (≤ 300 nm) represented the 8.51 ± 1.11 % of total identified microparticles. Lower microvesicle range (≤ 500 nm) represented
the 3.49 ± 0.17 % of total identified microparticles. Higher microvesicle range (> 500 nm) represented the 13.34 ± 1.43 % of total identified microparticles
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Circulating CNS-EVs isolated from cerebrospinal fluid
contain common EV markers previously compiled in
EVs specialized databases [37]. Fiandaca and colleagues
found that CNS-EVs released to the blood circulation
contain the CNS specific protein neural cell adhesion
molecule-L1 (CD171) [38]. Our data were consistent
with these previous results and a high number of com-
piled EV proteins from specialized databases were iden-
tified in PROSPR-CNS-EV enriched fractions. Likewise,
the CNS-specific protein CD171 was identified in both
Ultra-CNS-EV and PROSPR-CNS-EV fractions.
dFC was firstly described by van der Pol and colleagues
as the analysis of submicrometer particles using a specially
calibrated flow cytometer [39]. Recently, a new method
workflow of dFC was developed by Pospichalova and
colleagues to characterize the size distribution and
relative amount of enriched EVs [28]. Characterization
of PROSPR-CNS-EVs by dFC as described by Pospicha-
lova and colleagues demonstrated that more than 80 % of
the total material in EV preparations was positively
stained by the phospholipid-specific dye PKH26 what con-
firmed, as expected, the high presence of vesicles in
enriched PROSPR-CNS-EV fractions. Of note, dFC also
revealed that 77 % of the total particles analyzed were
found at the exosomal range (100 nm) indicating for the
first time that these vesicles are significantly more abun-
dant than microvesicles in CNS tissues.
Analysis of EVs from CNS tissues by LC-MS/MS will
not only uncover the protein candidates of the EVs
proteome involved in neuropathology but will also en-
able characterization of the degenerative posttransla-
tional modifications (DPMs) occurring in those proteins
[40, 41]. DPMs are considered as crucial events of sev-
eral neurodegenerative proteinopathies [42–46] notwith-
standing their presence and roles in CNS-EVs from in
vivo tissues have yet to be explored.
In a similar vein, lipid molecules are essential compo-
nents of bilayer membranes and are thus critical to
maintaining EV structural integrity, but can also act as
effector molecules in several brain signaling pathways
[47, 48]. Data from our PROSPR-CNS-EV lipidome ana-
lyses were consistent with previous EV profile reported by
Rappa and colleagues in immortalized cancer cells [18].
Three of the lipid isoforms identified in PROSPR-CNS-EVs
were novel species not previously reported in EV data-
bases, suggesting that these molecules may represent spe-
cific markers of CNS-derived EVs. Our study demonstrates
that PROSPR-CNS-EVs can be successfully characterized
Fig. 4 Analysis of PROSPR-CNS-EVs enriched from mouse brain tissue. a Venn diagram matched to mouse exosome proteins compiled in Exocarta [19]
and Funrich [24] corresponding to the 42 % of total identified proteins in mouse PROSPR-CNS-EV fractions. Mouse microvesicle proteins compiled in
Vesiclepedia [21] and EVpedia [22] corresponding to the 33 % of all identified proteins in mouse PROSPR-CNS-EV fractions. Finally, the 49.5 % of the EV
proteins found in mouse PROSPR-CNS-EVs were novel identifications not previously found in enriched/isolated EVs. b Funrich [24] site of expression
analysis of unique EV proteins from mouse PROSPR-CNS-EVs. c Funrich cellular origin categories of unique EV proteins from mouse PROSPR-CNS-EVs
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using lipidomic techniques, which may assist the future
identification of novel disease biomarkers, therapies and
prognostic tests that exploit lipid biology rather than pro-
tein targets [49]. Furthermore, lipidomic characterization
of PROSPR-CNS-EVs may allow the generation of novel
neurotherapeutic materials mimicking the currently un-
known lipoic composition of CNS-EVs [50, 51].
Conclusions
The novel methodological approach reported herein will
enable detailed characterization of the emergent roles
played by EVs in human neurobiology. We believe that
the simple, inexpensive and standardized application of
PROSPR to the analysis of CNS tissues will accelerate
progress in our understanding of intercellular communi-




All reagents were purchased from Sigma-Aldrich
(St Louis, MO, USA) unless stated otherwise. Protease
inhibitor cocktail tablets were obtained from Roche (Basel,
Switzerland) and sequencing-grade modified trypsin was
obtained from Promega (WI, USA).
Brain samples
Human brain tissues were generously provided by the
Fukushimura Brain Bank (Toyohashi, Aichi, Japan). In-
formed consent was obtained and all procedures were
approved by the ethics committee of the Fukushimura
hospital. The use of human materials was conducted in
accordance with the declaration of Helsinki. Brain tissue
samples were frozen in liquid nitrogen at the time of
autopsy and stored at −150 °C. Human temporal lobe
was dissected into small pieces of ~150 mg and larger
blood vessels and meninges were removed. Dissected
brain tissues from a male C57BL/6 J mouse (~40 mg)
were also used. Tissues were washed thrice in 1X PBS
for 10 min. All experimental procedures were approved
by the Institutional Review Board at Nanyang Techno-
logical University and were performed according to in-
stitutional guidelines.
PROSPR-based isolation of EVs from human CNS tissues
Homogenization of human CNS tissue
Homogenization of human CNS tissue was performed in
100 mM ammonium acetate (AA) buffer supplemented
with Complete Protease Inhibitor cocktail using a bullet
blender homogenizer (Next Advance, NY, USA) as
depicted in Fig. 5. Safe-lock tubes and metallic beads
(200 mg of 0.9–2.00 mm particles) were used throughout
the homogenization procedure. No denaturing agents were
used during this process in order to preserve EV integrity.
CNS tissues were initially homogenized at medium in-
tensity (speed < 6) in two cycles of 5 min each, using
500 μL fresh AA buffer per cycle. The sample was then
centrifuged at 15,000 x g for 10 min, the supernatant
was collected, and the pellet was re-suspended in 500 μL
fresh AA buffer for a second round of homogenization
for 5 min at high intensity (maximum speed). Next, the
sample was centrifuged at 15,000 x g for 10 min, the
supernatant was collected, and the pellet was subjected
to a final round of intense homogenization as described
before (after which any remaining pellet was discarded).
All homogenization procedure was performed at 4 °C.
Homogenization of mouse CNS tissue
Homogenization of mouse CNS tissue was performed as
indicated for human CNS tissue although following a
milder homogenization procedure. CNS tissue with
500 μL fresh 100 mM AA buffer and 40 mg metallic beads
was homogenized at medium intensity (speed < 6) for
5 min. Homogenized sample was centrifuged at 15,000 x g
for 10 min and the supernatant was collected. Pellet was
re-suspended in 500 μL fresh AA buffer and subjected to
a second round of homogenization for 5 min performed
at speed < 8. Homogenized sample was then centrifuged
at 15,000 x g for 10 min and supernatant was collected.
All homogenization procedure was performed at 4 °C.
PROSPR-based isolation of EVs
All supernatant fractions were then combined and the
EVs were enriched by PROSPR as previously described
[16]. Briefly, the combined supernatants were mixed with
four volumes of chilled acetone (−20 °C) and the mixture
was vortexed and centrifuged at 5000 × g for less than one
minute in order to pellet the precipitated water-soluble
proteins and other contaminants. Finally, the PROSPR
supernatants containing enriched CNS-derived EVs
were collected and dehydrated in a vacuum concen-
trator (Concentrator Plus, Eppendorf AG, Hamburg,
Germany) to obtain the PROSPR-CNS-EVs enriched
fraction. The dehydrated pellets were then directly
used or stored at −80 °C until further use.
Ultracentrifugation-based isolation of EVs from human
CNS tissues
Isolation of CNS EVs by ultracentrifugation was performed
as previously described [16] adapted to CNS tissues. Hu-
man brain tissue was homogenized in 100 mM AA buffer
as detailed above. Supernatant was then diluted with 1X
PBS and transferred to an ultra-centrifugation tube (5 mL)
containing 1 mL chilled sucrose (5 % solution). Ultra-
centrifugation was done at 200.000 × g, 4 °C overnight to
obtain the final Ultra-CNS-EVs enriched pellet.
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Lipidomic characterization of PROSPR-CNS-EVs
Lipidomic characterization of PROSPR-CNS-EVs was
performed as previously reported by Milne et al. [52] ex-
cept for minor modifications. PROSPR-CNS-EVs were
re-suspended in a mixture of 800 μL 0.1 N HCl:metha-
nol (1:1, w/w) and 400 μL of chloroform, then vortexed
for 1 min, and centrifuged at 18,000 × g for 5 min. The
chloroform lower-phase containing lipids was then aspi-
rated into a new tube and evaporated in a vacuum con-
centrator. The lipids were then reconstituted in 150 μL
methanol:chloroform (9:1, v/v). Finally, a 1.5 μL volume of
ammonium hydroxide was added to the sample to ensure
proper protonation for subsequent analysis by mass spec-
trometry. Lipid characterization by direct infusion ESI-
MS/MS was performed using a Thermo Scientific Inc.
Orbitrap Elite mass spectrometer (Bremen, Germany).
The sample was sprayed at a flow-rate of 1 μL/min using
a Thermo Scientific Inc. Ion Max API source.
Data were acquired over 4.5 min/run using LTQ Tune
Plus software (Thermo Scientific Inc., Bremen, Germany)
in either positive or negative mode. For both modes, data
acquisition was performed by alternating between Full
FT-MS (150–1100 m/z, resolution 120,000 [at 400 m/z],
with one μscan per spectrum) and FT-MS/MS with the 10
most intense ions above a 500 minimum signal threshold
being fragmented in collision-induced dissociation mode
at 35 % normalized collision energy (with an auto-
matic mass range selection, resolution 120,000 [at
400 m/z] and 1 μscan per spectrum). Dynamic exclu-
sion list was enabled with an exclusion duration of 45 s
and an exclusion list size of 30. Capillary temperature was
set at 250 °C and source voltage at 1.5 kV. The automatic
Fig. 5 Workflow of the methodology applied to enrich EVs from human CNS tissues. Dissected brain tissue is homogenized in two cycles of
medium and higher speed as depicted here. *PROSPR workflow was adapted from our previous report [16]. Obtained PROSPR-CNS-EVs were
characterized by lipidomics and proteomics as illustrated in this diagram
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gain control (AGC) target for FT-MS and MS/MS was set
at 1e106.
Proteomic characterization of PROSPR-CNS-EVs
In solution digestion PROSPR-CNS-EVs were lysed
and the constituent proteins were digested as previously
described [16] except for minor modifications. Dehy-
drated PROSPR-CNS-EVs were completely re-dissolved
in a 16 M urea, 50 mM ABB buffer, and then diluted 1:1
with bi-distilled water. The proteins were then reduced
with 10 mM dithiotreitol at 30 °C for 3 h and subse-
quently alkylated with 20 mM iodoacetamide for 45 min
at room temperature in the dark. Urea was then diluted
to < 1 M using 25 mM ABB and the proteins were
digested overnight at 30 °C with trypsin at 1:20 protein-
to-enzyme ratio (w/w). The reaction was quenched by
acidification to a 0.5 % final concentration of formic acid
(FA). Peptides were desalted using Waters Sep-pack
50 mg C18 cartridges (Waters, MA. USA) and the eluted
peptide solution was dried in a vacuum concentrator
(Eppendorf, Hamburg, Germany).
High-pressure liquid chromatography fractionation
Fractionation of peptides by high-pressure liquid chroma-
tography (HPLC) was performed as previously described
in [16] and [53]. Desalted peptides were re-dissolved in
200 μL mobile phase A (85 % acetonitrile (ACN), 0.1 %
acetic acid). Fractionation into a Fortis Amino column
(4.6 × 200 mm, 3 μm, Fortis Technologies Ltd., Cheshire,
UK) was performed using a Shimadzu Prominence UFLC
system with wavelength monitoring at 280 nm. Separation
of peptides was carried out using a 72-min gradient at a
flow-rate of 1 mL/min as follows; 0 % mobile phase B
(10 % ACN, 0.1 % FA) for 5 min, 0–20 % mobile phase B
for 25 min, 20–33 % mobile phase B for 10 min, 33–60 %
mobile phase B for 10 min, and 60–100 % mobile phase B
for 5 min, followed by 17 min at 100 % mobile phase B.
The collected fractions were then combined into consecu-
tive pairs or according to peak intensities and dried in a
vacuum concentrator.
LC-MS/MS
Peptides were reconstituted in 3 % ACN, 0.1 % FA before
being subjected to LC-MS/MS analysis using a Dionex
UltiMate 3000 UHPLC system coupled with an Orbitrap
Elite mass spectrometer (Thermo Scientific Inc., Bremen,
Germany). The sample was sprayed using a Michrom
Thermo CaptiveSpray nanoelectrospray ion source
(Bruker-Michrom Inc., Auburn, USA) with a source volt-
age of 1.5 kV. Sample peptides (~2 μg per injection) were
separated at a flow rate of 300 nL/min using a reverse-
phase Acclaim PepMap RSL column (75 μm ID× 15 cm,
2 μm particle size, Thermo Scientific Inc.) maintained at
35 °C. Separation of peptides was performed using a 60-
min gradient starting with 3 % mobile phase B (90 %
ACN, 0.1 % FA) and 97 % mobile phase A (0.1 % FA
in water) for 1 min, 3–35 % mobile phase B for 47 min,
35–50 % mobile phase B for 4 min. The gradient was then
increased to 80 % mobile phase B over 6 s, maintained
under isocratic conditions for 78 s, then reverted to initial
conditions over 6 s, and again maintained under isocratic
conditions for 6.5 min.
Data acquisition in positive mode was performed using
LTQ Tune Plus software (Thermo Scientific Inc., Bremen,
Germany) alternating between full FT-MS (350–1600 m/z,
resolution 60,000 [at 400 m/z], with one μscan per
spectrum) and FT-MS/MS (150–2000 m/z, resolution
15,000 [at 400 m/z], one μscan per spectrum). The 10 most
intense ions with a threshold of 500 counts were fragmen-
ted in high-energy collisional dissociation (HCD) mode
using 32 % normalized collision energy. The AGC target
for full FT-MS and MS/MS was set to 1e + 06, precursor
ion charge state screening was activated, and capillary
temperature was set to 250 °C.
Characterization of PROSPR-CNS-EVs by dFC
PROSPR-CNS-EV fractions were concentrated to ~50 μL
using the vacuum concentrator. Fluorescent labeling of
PROSPR-CNS-EVs was performed using the phospholipid-
specific dye PKH26 according to manufacturer’s instruc-
tions (PKH26-GL, Sigma-Aldrich, St Louis, MO, USA).
Cyan-ADP flow cytometer (Beckman Coulter, CA., USA)
equipped with three solid state lasers (407 nm, 488 nm,
and 633 nm) was used for data acquisition. Fluorochrome
excitation at 488 nm and acquisition at 585 nm were kept
parameters during data acquisition of dyed EVs. Three EVs
reference latex beads of 0.1 μM, 0.3 μM and 0.5 μM from
Beckman Coulter (CA, USA) were used to set PMT volt-
ages and thresholds for light scattering. Non-labeled
PROSPR-CNS-EV samples, bi-distilled water and PBS buf-
fer were used as negative controls. All measurements were
performed in log mode with noise levels set to side scatter
at 0.08. Microparticles were measured setting the stop con-
dition for PE TruCount particles at 5.000 and 20.000
events. All dFC experiments were performed in triplicate.
Bioinformatics and data analysis
Raw MS/MS data from the lipidomic and proteomic exper-
iments were de-isotoped and converted into mascot generic
format files using Thermo Proteome Discoverer version
1.4.1.14 (Thermo Scientific Inc., Bremen, Germany). Identi-
fication of lipids was conducted using in-house software
and LipidBlast [54] in high-throughput mode together with
NIST MSPepSearch (http://peptide.nist.gov/). Database
searches for lipid identification used all available LipidBlast
libraries for positive and negative modes. Precursor ion
tolerance and fragment peak tolerance were set at
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0.01 m/z. Relative quantification of lipid families was
based on the absolute number of identifications in a total
of 5 replicates from each analyzed mode (Additional file 1:
Dataset 1). Database searches for proteomic data were
performed using an in-house Mascot server (version
2.3.02, Matrix Science, MA, USA) with a precursor ion
tolerance of 10 ppm and fragment peak tolerance of
0.05 Da as previously indicated [55]. Uniprot human data-
base (downloaded on 15th July of 2015, 90478 sequences
and 35.890.546 residues) was used for database search.
Two missed trypsin cleavage sites were tolerated. Carba-
midomethylation (C) was set as fixed modification and
deamidation (NQ) and oxidation (M) were set as variable
modifications. Peptides with Mascot score >15 were used
to generate the peptide list in all tested human conditions.
Additionally, Uniprot mouse database (downloaded on
19th February of 2016, 101382 sequences and 43.874.034
residues) was used for database search. The rest of search
conditions for mouse PROSPR-CNS-EV fractions were
the same already described for human database search.
To filter non-confident peptide and protein identifica-
tions in human PROSPR-CNS-EVs, whole brain prote-
ome and Ultra-CNS-EVs; only those proteins identified
in at least two replicates were reported. Label-free quan-
titation of protein abundance was conducted using the
exponentially modified protein abundance index (emPAI)
in Mascot [23] and functional enrichment analyses were
performed in the open software Funrich [24]. Statistical
cut-off of enrichment analyses in FunRich software was
kept as default with a p-value <0.05 after Bonferroni cor-
rection. Venn diagrams were performed using the open
software Venny [56].
Data availability
The lipidomic and proteomic data generated in this
study have been made publicly available through the
ProteomeXchange Consortium [57] via the partner re-
pository PRIDE. Identifier: PXD003288.
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Additional file 1: Dataset 1. List of lipid isoforms identified by direct
infusion ESI-MS/MS in PROSPR-CNS-EVs. Database searches for lipid
identification used all available LipidBlast libraries for positive and negative
modes. Precursor ion tolerance and fragment peak tolerance were set at
0.01 m/z. Absolute number of identifications was generated considering 5
replicates from each analyzed mode. (XLS 31 kb)
Additional file 2: Dataset 2. List of lipid isoforms identified by direct
infusion ESI-MS/MS in whole brain. List of lipid isoforms identified by
direct infusion ESI-MS/MS in PROSPR-CNS-EVs. Database searches for lipid
identification used all available LipidBlast libraries for positive and negative
modes. Precursor ion tolerance and fragment peak tolerance were set at
0.01 m/z. Absolute number of identifications was generated considering 5
replicates from each analyzed mode. (XLS 28 kb)
Additional file 3: Dataset 3. List of proteins identified by LC-MS/MS in
PROSPR-CNS-EVs. Database searches was performed using an in-house
Mascot server (version 2.3.02, Matrix Science, MA, USA) with a precursor
ion tolerance of 10 ppm and fragment peak tolerance of 0.05 Da. Uniprot
human database (downloaded on 15th July of 2015, 90478 sequences
and 35.890.546 residues) was used for database search. Two missed trypsin
cleavage sites were tolerated. Carbamidomethylation (C) was set as fixed
modification and deamidation (NQ) and oxidation (M) were set as variable
modifications. Peptides with Mascot score >15 were used to generate the
peptide list in all tested human conditions. (XLS 543 kb)
Additional file 4: Dataset 4. List of proteins identified in human whole
brain. Database searches was performed using an in-house Mascot server
(version 2.3.02, Matrix Science, MA, USA) with a precursor ion tolerance of
10 ppm and fragment peak tolerance of 0.05 Da. Uniprot human database
(downloaded on 15th July of 2015, 90478 sequences and 35.890.546
residues) was used for database search. Two missed trypsin cleavage sites
were tolerated. Carbamidomethylation (C) was set as fixed modification and
deamidation (NQ) and oxidation (M) were set as variable modifications.
Peptides with Mascot score >15 were used to generate the peptide list
in all tested human conditions. (XLS 286 kb)
Additional file 5: Figure S1. Characterization of whole brain proteome.
a. Venn diagram analysis of whole brain proteome matched to records in
Exocarta [19], Vesiclepedia [21] and EVpedia [22] databases. b. Venn diagram
analysis of whole brain proteome matched to the 568 unique proteins
obtained from the comparison between PROSPR-CNS-EVs versus proteins
compiled in Exocarta [19] and Vesiclepedia [21] and to the 119
unique proteins obtained in common with Ultra-CNS-EVs fractions
(see in Fig. 2d the origin of these unique CNS-EV proteins). (TIF 1726 kb)
Additional file 6: Dataset 5. List of 72 novel identified EV proteins from
CNS tissue present in whole brain proteome. List of 54 novel identified
EV proteins from CNS tissue only present in EV-enriched fractions. (XLS 322 kb)
Additional file 7: Dataset 6. List of proteins identified in PROSPR-CNS-EVs
that were not previously reported in EV databases. (XLS 146 kb)
Additional file 8: Dataset 7. List of proteins identified in PROSPR-CNS-EVs
from mouse brain. Database searches was performed using an in-house
Mascot server (version 2.3.02, Matrix Science, MA, USA) with a precursor ion
tolerance of 10 ppm and fragment peak tolerance of 0.05 Da. Uniprot
mouse database (downloaded on 19th February of 2016, 101382 sequences
and 43.874.034 residues) was used for database search. Two missed trypsin
cleavage sites were tolerated. Carbamidomethylation (C) was set as fixed
modification and deamidation (NQ) and oxidation (M) were set as variable
modifications. Peptides with Mascot score >15 were used to generate the
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